Vivanza Biosciences Ltd (VIVANZA)

Loading page…

Vivanza Biosciences Ltd (VIVANZA) · mywealthgrid

About

Vivanza Biosciences Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹1

Market cap

₹7 Cr

P/E

17.4×

P/B

1.6×

Dividend yield

ROE

9.4%

ROCE

13.1%

Debt / equity

2.34

OPM

0.6%

EPS (TTM)

₹0.1

Book value

₹1.1

52-week high

—

52-week low

—

818 historical price candles were omitted because the exchange source has not been verified.

₹1.7-2.3%1Y

Quick read

rule-based

Pros

+Profit CAGR of 37.3% over the last 5 years
+Revenue CAGR of 63.6% over the last 5 years

Cons

−Low return on equity of 2.1% (3-yr avg)
−Thin operating margin of 0.6%
−Heavily leveraged (debt/equity 2.3)
−Low promoter holding of 20%

Research score

Structured signal from quality, growth, valuation and momentum.

43/100

Business quality: 12
Growth: 50
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	10	10	18	28	7	116
COGS	9	10	17	26	7	114
Gross profit	1	1	1	2	1	1
	1	1	1	1	1	1
	0	-0	1	1	-0	1
OPM %	1%	-0.8%	3.7%	3.8%	-5%	0.6%
Depreciation	0	0	0	0	0	0
Interest	0	0	0	0	0	0
	1	1	0	0	0	0
Profit before tax	0	0	1	1	-1	1
Tax	0	0	0	0	0	0
Tax %	41.7%	0%	16.7%	21.4%	1.5%	27.8%
	0	0	1	1	-1	0
PAT margin %	0.8%	3.2%	3.4%	2%	-9%	0.3%
EPS (₹)	0.2	0.8	1.5	0.1	-0.2	0.1
EPS adjusted (₹)	0	0.1	0.2	0.1	-0.2	0.1
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	4	4	4	4	4	4
Reserves	—	-1	-1	0	1	-0	0
	—	0	3	8	5	9	10
	—	5	7	10	10	4	8
Total equity & liabilities	—	8	13	22	20	16	22
	2	2	2	2	2	2	2
CWIP	—	—	—	—	0	0	0
Investments	—	0	0	0	0	0	0
	—	6	11	20	17	14	20
Total assets	—	8	13	22	20	16	22

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-3	-1	-1	2	-3	-1
	-0	0	0	-0	-0	-0
	2	1	1	-2	2	1
Net cash flow	-0	0	0	0	-0	-0
Free cash flow	-3	-1	-1	2	-3	-1
CFO / Operating profit %	—	—	-143.9%	190.7%	—	-172.6%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	7.5%	7.1%	7.4%	6.8%	8.1%	1.3%
EBITDA margin %	1%	-0.8%	3.7%	3.8%	-5%	0.6%
EBIT margin %	0.9%	-0.9%	3.7%	3.8%	-5.1%	0.6%
PAT margin %	0.8%	3.2%	3.4%	2%	-9%	0.3%
Working capital
Receivable days	231	275	256	151	396	39
Inventory days	26	92	55	28	121	11
Payable days	154	207	211	116	140	23
NWC days	103	160	99	64	377	27
Leverage
Current ratio	0.95	1.44	1.15	1.29	1.35	1.13
Debt to EBITDA	3.6	—	12.11	4.83	—	13.96
Debt to equity	0.11	0.8	1.95	1.11	2.18	2.34
Interest coverage	1.3	1.8	2.7	2.7	-0.9	2.9
Asset turnover	1.17	0.81	0.79	1.43	0.45	5.25
Return ratios
Return on assets %	0.9%	2.6%	2.7%	2.8%	-4.1%	1.8%
Return on capital employed %	18.7%	16%	19.6%	17.3%	-4.4%	13.1%
Return on equity %	2.5%	9.5%	14.7%	11.9%	-16.9%	8.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	47.29%	44.9%	43.24%	40.05%	39.86%	20.02%	20.02%	20.02%	20.02%	20.02%	20.02%	20.02%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	52.71%	55.1%	56.76%	59.95%	60.14%	79.98%	79.98%	79.98%	79.98%	79.98%	79.98%	79.98%
No. of shareholders	—	—	—	—	—	—	—	—	20,170	19,822	19,461	19,254

Promoter holding down 27.27 percentage points since Sep 2023.

65 deals · 31 Oct 2023 – 26 May 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
26 May 2025	JAGDISH LAL	Bulk	BSE	Sell	2,63,386	₹2.45	₹0.06 Cr
6 Feb 2025	RAJ KUMAR BAID	Bulk	BSE	Sell	2,22,222	₹2.39	₹0.05 Cr
8 Jan 2025	VISHAL CHINUBHAI SUTHAR HUF	Bulk	BSE	Sell	10,40,315	₹3.67	₹0.38 Cr
8 Jan 2025	BIBHAS BHAGWANDAS ASAR	Bulk	BSE	Sell	3,00,000	₹3.61	₹0.11 Cr
8 Jan 2025	SWATI VISHAL SUTHAR	Bulk	BSE	Sell	2,43,859	₹3.68	₹0.09 Cr
8 Jan 2025	VISHAL CHINUBHAI SUTHAR HUF	Bulk	BSE	Buy	3,000	₹3.60	₹0.00 Cr
1 Jan 2025	JITEN KUMAR BISWAS	Bulk	BSE	Buy	2,18,000	₹3.69	₹0.08 Cr
27 Dec 2024	KALPESH VITHALDAS RAMI	Bulk	BSE	Sell	3,29,783	₹3.48	₹0.11 Cr
27 Dec 2024	SWATI VISHAL SUTHAR	Bulk	BSE	Sell	2,64,209	₹3.49	₹0.09 Cr
26 Dec 2024	ANANT WEALTH CONSULTANTS PRIVATE LIMITED	Bulk	BSE	Sell	4,06,881	₹3.16	₹0.13 Cr

1–10 of 65

1 / 7

Mr. Jaynedra MehtaManaging Director
Jainil BhattChief Financial Officer
Mr. Hemant Amrish ParikhNon - Executive Non -Independent Director
Ms. Rina KumariNon - Executive Independent Director
Mr. Hitesh RijwaniNon - Executive Independent Director
Mr. Sarang Bharatbhai PathakNon - Executive Non -Independent Director
Mr. Vishal Sureshbhai KatarmalCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Vivanza Biosciences Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results7 Aug 2026

1

Face value ₹10 → ₹124 Mar 2023 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

19 announcementsExport CSV

28 Sept 2026, 10:47 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	7.5%	7.1%	7.4%	6.8%	8.1%	1.3%
EBITDA margin %	1%	-0.8%	3.7%	3.8%	-5%	0.6%
EBIT margin %	0.9%	-0.9%	3.7%	3.8%	-5.1%	0.6%
PAT margin %	0.8%	3.2%	3.4%	2%	-9%	0.3%
Working capital
Receivable days	231	275	256	151	396	39
Inventory days	26	92	55	28	121	11
Payable days	154	207	211	116	140	23
NWC days	103	160	99	64	377	27
Leverage
Current ratio	0.95	1.44	1.15	1.29	1.35	1.13
Debt to EBITDA	3.6	—	12.11	4.83	—	13.96
Debt to equity	0.11	0.8	1.95	1.11	2.18	2.34
Interest coverage	1.3	1.8	2.7	2.7	-0.9	2.9
Asset turnover	1.17	0.81	0.79	1.43	0.45	5.25
Return ratios
Return on assets %	0.9%	2.6%	2.7%	2.8%	-4.1%	1.8%
Return on capital employed %	18.7%	16%	19.6%	17.3%	-4.4%	13.1%
Return on equity %	2.5%	9.5%	14.7%	11.9%	-16.9%	8.9%

Date	Category	Subject	Filing
28 Sept 2026, 10:47 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
12 Sept 2026, 1:25 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
12 Sept 2026, 11:49 am	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
11 Sept 2026, 4:04 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
20 Aug 2026, 11:42 am	Company Update General	Announcement Under Regulation 30 (LODR)-Newspaper Publication	PDF
19 Aug 2026, 11:58 am	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
19 Aug 2026, 11:45 am	AGM/EGM AGM	Notice Of The 44Th Annual General Meeting (''''AGM'''') And Annual Report Of The Company For The Financial Year 2025-26	PDF
17 Aug 2026, 4:06 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting Held On 17.08.2026	PDF

Vivanza Biosciences Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

1

Announcements

Not in the F&O segment

No fund holdings on record

1

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Vivanza Biosciences Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Stock splits1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1

1

1